TransMedics Group Inc.

TransMedics Group Inc. is a U.S.-based health care company founded in 2008 that markets the innovative Organ Care System (OCS), a portable organ perfusion system designed to improve transplant outcomes. The company earns revenue from hardware sales and recurring consumable services provided to hospitals and transplant centers. Led by CEO Dr. Christopher J. Love, TransMedics has captured an estimated 15-20% share of the U.S. organ perfusion market while expanding its clinical footprint. Its future initiatives include launching additional organ modules and entering international markets to drive further growth.

TransMedics has no share-repurchase program; Item 5 of the 10-K states the Company did not purchase any of its registered equity securities during the period from September 30, 2025 to December 31, 2025.